Adaptimmune Therapeutics PLC (ADAPY) Cash flow
Market cap
$5.73M
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 9 | 11 | 16 | 11 | 10 | 21 | 18 | 12 | 12 |
| Cash from operations | -48 | -54 | -104 | -112 | -54 | 11 | -142 | -141 | -73 |
| Capital expenditures | -12 | -25 | -4 | -2 | -2 | -9 | -29 | -5 | -1 |
| Cash from investing | 18 | -126 | -17 | 95 | -279 | 76 | 89 | 177 | -59 |
| Proceeds from issuance of term debt, net | - | - | - | - | - | - | - | - | 50 |
| Cash from financing | 0 | 104 | 103 | 0 | 340 | 3 | 13 | 1 | 79 |
| Free cash flow | |||||||||
| FCF margin (%) |